ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1104

Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial

Scott Baumgartner, Raymond Zheng, Mark Harnett and Jay Kranzler, Urica Therapeutics Inc., New York, NY

Meeting: ACR Convergence 2023

Keywords: clinical trial, gout, hyperuricemia, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Dotinurad is a potent and selective URAT1 inhibitor that has been approved as a once-daily drug for the treatment of hyperuricemia with or without gout in Japan since 2020, based on results of 17 clinical trials conducted in Japan with more than 1000 patients exposed with up to 58 weeks in treatment duration. In the Japanese dossier, 4mg dotinurad reduced serum urate to < 6 mg/dL in 100% of patients after long-term treatment. No significant cardiovascular, renal or hepatic adverse events were observed with dotinurad at approved doses in the Japanese studies. This Phase 1 study is the first performed in a ‘western’ population, initiating the development of dotinurad for eventual use in North America and EU.

Methods: Randomized, double-blind, placebo-controlled, three-period crossover multiple-dose in 15 healthy male and female volunteers (age 18 to 55 years), doses included placebo, 1, 2, 4, and 8 mg once-daily in the morning for 4 days. Serial blood samples were collected to measure pharmacokinetic concentrations of dotinurad as well as serum and urine uric acid levels.Maximum concentration (Cmax), area under the curve (AUC0-τ), half-life (t1/2) were determined.Study drug accumulation from Day 1 to Day 4 was assessed. Safety monitoring was performed throughout.

Results: Dotinurad concentrations exhibited an increase in dotinurad exposure for AUC and Cmax that was proportional to dose.Plasma-concentration time profiles following multiple oral doses of dotinurad were characterized by a rapid absorption phase, with median Tmax of 2.5 to 3 hours. When normalized for dose, Cmax was consistent across the dose range. The rate of elimination appeared to be consistent across the dose groups on Day 4, with geometric mean T1/2 values ranging from 7.73 to 8.82 hours. The range of accumulation ratios for AUC0-τ and Cmax were also found to be similar across all doses administered (1.18 to 1.26 and 1.07 to 1.21, respectively), demonstrating that dotinurad shows little to no accumulation in the plasma following multiple daily dosing.

As dotinurad dose increased, a respective reduction in serum urate concentrations and overall exposure to urate was observed. Steady state of reduced serum urate levels was achieved in day 3. Up to 90% sUA reduction from baseline was observed with dotinurad treatment.

Dotinurad was well tolerated with no observed serious adverse event. No treatment related adverse event was observed with 1-4 mg of dotinurad.

Conclusion: Following 4 consecutive once-daily treatments, dotinurad has exhibited a pharmacokinetic profile, in western healthy subjects, comparable to that from Japanese healthy men. All tested doses of dotinurad (1, 2, 4 & 8 mg QD) significantly reduced serum urate levels. These results support the potential application of dotinurad as a once-daily treatment for hyperuricemia in western population. Another clinical study is currently underway to further establish the safety, efficacy and drug interaction of dotinurad in U.S. gout patients.

Supporting image 1

Mean serum urate concentrations across all days in the pharmacodynamic population


Disclosures: S. Baumgartner: Urica Therapeutics Inc., 2; R. Zheng: Urica Therapeutics Inc., 3; M. Harnett: Urica Therapeutics Inc., 2; J. Kranzler: Urica Therapeutics Inc., 3.

To cite this abstract in AMA style:

Baumgartner S, Zheng R, Harnett M, Kranzler J. Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/dotinurad-a-potent-and-selective-uricosuric-agent-exhibited-promising-pharmacokinetics-and-pharmacodynamic-profiles-to-significantly-reduce-serum-urate-levels-following-once-daily-dosing-in-healthy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dotinurad-a-potent-and-selective-uricosuric-agent-exhibited-promising-pharmacokinetics-and-pharmacodynamic-profiles-to-significantly-reduce-serum-urate-levels-following-once-daily-dosing-in-healthy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology